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Background: To characterize prognostic and risk factors of central nervous system (CNS) metastases in patients
with epithelial ovarian cancer (EOC).
Methods: A retrospective analysis of Xijing Hospital electronic medical records was conducted to identify patients
with pathologically confirmed EOC and CNS metastases. In addition to patient demographics, tumor pathology,
treatment regimens, and clinical outcomes, we compared putative cancer stem cell marker CD133 expression
patterns in primary and metastatic lesions as well as in recurrent EOC with and without CNS metastases.
Results: Among 1366 patients with EOC, metastatic CNS lesions were present in 29 (2.1%) cases. CD133 expression
in primary tumor was the only independent risk factor for CNS metastases; whilst the extent of surgical resection of
primary EOC and platinum resistance were two independent factors significantly associated with time to CNS
metastases. Absence of CD133 expression in primary tumors was significantly associated with high platinum
sensitivity in both patient groups with and without CNS metastases. Platinum resistance and CD133 cluster
formation in CNS metastases were associated with decreased survival, while multimodal therapy including
stereotactic radiosurgery (SRS) for CNS metastases was associated with increased survival following the diagnosis of
CNS metastases.
Conclusions: These data suggest that there exist a positive association between CD133 expression in primary EOC,
platinum resistance and the increased risk of CNS metastases, as well as a less favorable prognosis of EOC. The
absence of CD133 clusters and use of multimodal therapy including SRS could improve the outcome of metastatic
lesions. Further investigation is warranted to elucidate the true nature of the association between platinum
sensitivity, CD133 expression, and the risk and prognosis of CNS metastases from EOC.
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The estimated incidence of central nervous system
(CNS) metastases in patients with epithelial ovarian can-
cer (EOC) is 1.01% (range from 0.49% - 2.2%) [1]. Re-
cently, an increased incidence of CNS metastases in
EOC has been reported [2-4], possibly due to a result of
better control of the primary cancer, advances in CNS
imaging techniques, and use of platinum-based che-
motherapies [4]. Platinum compounds do not pass the
blood–brain barrier (BBB), leaving the CNS more vul-
nerable to the growth of cancer cells [4], and reportedly
platinum could damage the BBB facilitating metastatic
cancer cell entry [5]. Increasing prevalence of CNS metas-
tases associated with EOC underscores the importance of
and the need for a better understanding of this clinical
entity. However, in most centers, diagnostic brain imaging
is not a routine procedure during the follow-up workup
for EOC, and the standard monitor tools such as CA-125
do not reliably predict CNS metastases.
It has been shown that prognostic factors for EOC pa-
tients with CNS metastases vary. Thus, a high performance
status [6,7], absence of extracranial lesions accompanying
CNS metastases [8,9], single metastases [7,8], platinum
sensitivity [7], a longer time to develop CNS metastases
[10], recursive partitioning analysis class [11], and a
multimodal therapy for CNS lesions [9,11,12] are often
associated with a more favorable prognosis. CD133 (pro-
minin-1), a 5-transmembrane glycoprotein [13] that is a
putative marker for cancer stem cells (CSCs) in solid tu-
mors including ovarian cancer, has been thought to define
a subpopulation of tumor-initiating cells with enhanced
resistance to platinum [14-16]. CD133 expression was
shown to be an unfavorable prognostic factor for overall
and disease-free survival in patients with ovarian cancer,
which is also associated with poor response to platinum-
based chemotherapy [17]. However, CD133 expression
has not been evaluated in patients with CNS metastases.
In addition, as a marker for “stemness”, CD133 is shown
to be associated with brain tumor stem cells that play key
roles in both brain tumor initiation and recurrence because
of their capacity for self-renewal and inherent chemo- and
radio-resistance [18]; but limited data are available on its
role in tumor metastasis.
In this study we examined possible predictors of CNS
metastases associated with EOC, and attempted to de-
fine a subgroup of vulnerable patients for whom special
attention should be paid when monitoring and managing
disease progression and CNS metastases.
Methods
Patients
Patient records at Xijing Hospital (Xi’an, People’s Republic
of China) between January 2002 and December 2011 were
included in the study if they had pathologically confirmedEOC. Patients excluded from the study were those with 1)
a past history of malignancy other than EOC, 2) a syn-
chronous primary tumor of other organs and 3) a non-
epithelial histologic type of ovarian cancer. Demographic,
clinical, and pathologic data related to the primary cancer
were obtained from the institution’s medical records
database. Patients were divided into platinum sensitive
(complete clinical remission with a treatment-free in-
terval >6 months after prior platinum therapy) or plati-
num resistant (progression or relapse within 6 months)
groups [7,17]. Among all the 1366 patients with EOC,
29 with CNS malignancies were identified. The patients’
demographic and clinical characteristics were reeva-
luated regarding the presence of CNS metastases. Du-
ring the study period, there was no established treatment
protocol for these patients with CNS metastases whose
treatments were retrospectively reviewed. Thirty-one
pathology-matched EOC patients with at least 1 relapse of
disease but without CNS metastases were used as the con-
trol. Approval was obtained from the Institutional Review
Board of Xijing Hospital, Fourth Military Medical Univer-
sity to perform this study and to use archived material for
research purposes.
Immunohistochemistry
Immunohistochemistry was done as previously described
[17]. Briefly, rabbit polyclonal antibody against CD133
(Abcam, Cambridge, UK) was used to detect CD133 ex-
pression in the EOC tissues of all patients with (N = 29)
and without (N = 31) CNS metastases and the metastatic
CNS tumor tissues obtained during neurosurgery (N = 19),
using the standard two-step indirect immunohistochemi-
cal staining method. We used the glioblastoma tissue as a
positive control of CD133 (Figure 1F). Omitting CD133
antibody during the primary antibody incubation served as
a negative control (Figure 1E).
Assessment of CD133 expression was done indepen-
dently by two observers (BLL and HC) blinded to clinico-
pathological information. Presence of either membrane
and/or cytoplasmic staining were considered a positive
signal, and the score of each sample was calculated as a
mean proportion of positive cells (range, 0-100%) in two
continuous sections. For statistical analysis, all cases were
divided into CD133- (0% CD133+ tumor cells) and
CD133+ (>0% CD133+ tumor cells, i.e. containing at least
one CD133+ cell) [17,19].
Statistical analysis
The time to diagnosis of CNS metastases was calculated
from the time of primary cancer surgery to the time of im-
aging diagnosis of CNS lesions. Overall survival (OS) after
the diagnosis of CNS metastases was calculated from the
time of imaging diagnosis to the time of death as a result
of any cause. Patients who were alive at the time of the last
Figure 1 Representative example of CD133 immunoreactivity pattern in ovarian cancer and CNS metastases (original magnification,
x40). (A) Cell membrane expression in ovarian serous cystadenocarcinoma. (B) Cell membrane and cytoplasmic expression in ovarian mucinous
cystadenocarcinoma. (C) Positive single cell expression pattern in CNS metastases from ovarian cancer. (D) Positive cluster formation in CNS
metastases from ovarian cancer (original magnification, x10, insert showing higher magnification, x40). (E) Negative control. (F) Positive control
of glioblastoma.
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of survival was estimated using the Kaplan-Meier method.
Differences in survival were tested by the log-rank test for
univariate comparisons. A multivariate analysis with Cox
proportional hazards model was done to establish inde-
pendent predictor(s) for time to CNS metastases and OS
after CNS metastases, whereas a multivariate analysis with
binary and multinomial logistic regression was done to es-
tablish risk factors for the development of CNS metastases.
To test whether frequency distributions differed across
categorical variables, the Fisher exact test was used. Statis-
tical significance was set at P <0.05, based on N = 29 cases,
unless indicated otherwise. Statistical analysis was per-
formed using SPSS software (version 16.0, SPSS, Inc.,
Chicago, IL, USA).Results
Patient characteristics
Of 1366 patients diagnosed with EOC, 29 (2.1%) devel-
oped CNS metastases. The major clinical characteristics
of these 29 patients at the time of diagnosis of primary
cancer are summarized in Table 1. The median age was
57 years (range from 37 to 74 years). All patients but 1
had received initial platinum-based chemotherapy. De-
mographic and clinical features were not significantly
different between the EOC patients with CNS metastases
and control group (Table 2).
Diagnosis of CNS metastases was based on CNS im-
aging abnormalities in all patients and was pathologically
confirmed after neurosurgery in 19 patients. The patient
characteristics at the time of diagnosis of CNS metastases
Table 1 Major clinical characteristics related to primary
EOC and its association with CD133 expression







<60 10 (62.5) 6 (37.5) 16
> = 60 5 (38.5) 8 (61.5) 13
FIGO stage 1.000
1,2 2 (66.7) 1 (33.3) 3
3,4 13 (50.0) 13 (50.0) 26
Pathology of primary cancer 0.837†
Serous 8 (50.0) 8 (50.0) 16
Mucinous 2 (100) 0 (0) 2
Endometrioid 1 (50.0) 1 (50.0) 2
Clear cell 1 (100) 0 (0) 1
Mixed
epithelial
2 (40.0) 3 (60.0) 5
Undifferentiated 1 (66.7) 2 (33.3) 3
Histological grade* 0.640
1,2 3 (60.0) 2 (40.0) 5
3, 8 (44.4) 10 (55.6) 18
Extent of surgical resection 0.477
TAH + BSO 13 (56.5) 10 (43.5) 23
Limited 2 (40.0) 3 (60.0) 5
Biopsy 0 (0) 1 (100) 1
Lymph node metastasis 0.812
Yes 9 (50.0) 9 (50.0) 18
No 6 (54.5) 5 (45.5) 11
Ascites at the time of primary surgery 0.893
Yes 10 (52.6) 9 (47.4) 19
No 5 (50.0) 5 (50.0) 10
Adjuvant therapy 0.397
Chemotherapy 14 (56.0) 11 (44.0) 25
Chemotherapy
+ Radiotherapy
1 (66.7) 2 (33.3) 3
None 0 (0) 1 (100) 1
Platinum sensitivity 0.006
Sensitive 12 (75.0) 4 (25.0) 16
Resistant 2 (16.7) 10 (83.3) 12
Abbreviations: TAH Total abdominal hysterectomy, BSO Bilateral salpingo-
oophorectomy.
*Where data were available.
†P value was caculated by comparing serous vs. non-serous groups.
Table 2 Major clinical characteristics and CD133
expression of EOC patients with vs. without CNS
metastases






<60 16 (55.2) 15 (48.4)
> = 60 13 (44.8) 16 (51.6)
FIGO stage 0.666
1,2 3 (10.3) 2 (6.5)
3,4 26 (89.7) 29 (93.5)
Pathology of primary cancer 0.979†
Serous 16 (55.2) 17 (54.8)
Mucinous 2 (6.9) 2 (6.5)
Endometrioid 2 (6.9) 2 (6.5)
Clear cell 1 (3.4) 2 (6.5)
Mixed epithelial 5 (17.2) 5 (16.1)
Undifferentiated 3 (10.3) 3 (9.7)
Histological grade* 0.724
1,2 5 (21.7) 4 (16.7)
3, 18 (78.3) 20 (83.3)
Extent of surgical resection 0.572
TAH + BSO 23 (79.3) 26 (83.9)
Limited 5 (17.2) 5 (16.1)
Biopsy 1 (3.4) 0 (0)
Lymph node metastasis 0.313
Yes 18 (62.1) 23 (74.2)
No 11 (37.9) 8 (25.8)
Ascites at the time of primary surgery 0.650
Yes 19 (46.3) 22 (52.6)
No 10 (53.7) 9 (47.4)
Adjuvant therapy 0.674
Chemotherapy 25 (86.2) 24 (77.4)
Chemotherapy +
Radiotherapy
3 (10.3) 5 (16.1)
None 1 (3.4) 2 (6.5)
Platinum sensitivity 0.516
Sensitive 16 (57.1) 19 (65.5)
Resistant 12 (42.9) 10 (34.5)
CD133 expression 0.018
Negative 15 (51.7) 25 (80.6)
Positive 14 (48.3) 6 (19.4)
Abbreviations: TAH Total abdominal hysterectomy, BSO Bilateral salpingo-
oophorectomy.
*Where data were available.
†P value was caculated by comparing serous vs. non-serous groups.
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of CNS metastases was 59 years (range from 39 to
76 years). Neurological deficits (including motor, sen-
sory or cranial nerve damage), headache (with/without
Table 3 Major clinical characteristics related to CNS metastases and its association with CD133 expression
Parameter No. of patients (%)* P value† P value‡ P value§
CD133-negative
expression
CD133-positive expression NA Total
Total Single cell Cluster
Age at the time of CNS metastasis(yrs) 0.228 0.342 1.000
<60 3 (27.3) 8 (72.7) 2 (18.2) 6 (54.5) 4 15
> = 60 0 (0) 8 (100.0) 2 (25.0) 6 (75.0) 6 14
KPS score 1.000 0.869 1.000
> = 80 1 (11.1) 8 (88.9) 2 (22.2) 6 (66.7) 5 14
<80 2 (20.0) 8 (80.0) 2 (20.0) 6 (60.0) 5 15
No. of metastases 0.546 0.149 0.118
Single 2 (25.0) 6 (75.0) 3 (37.5) 3 (37.5) 3 11
Multiple 1 (9.1) 10 (90.9) 1 (9.1) 9 (81.8) 7 18
Leptomeningeal dissemination / / /
Yes / / / / 1 1
No 2 11 2 9 2 15
Unknown 1 5 2 3 7 13
Prior cancer relapse before the diagnosis of CNS metastasis 1.000 0.728 0.529
Yes 0 (0) 3 (100.0) 0 (0) 3 (100.0) 2 5
No 3 (18.8) 13 (81.3) 4 (25.0) 9 (56.3) 8 24
Presence of extracranial disease 1.000 1.000 1.000
Yes 1 (11.1) 8 (88.9) 2 (22.2) 6 (66.7) 4 13
No 2 (20.0) 8 (80.0) 2 (20.0) 6 (60.0) 6 16
CD133 expression in primary ovarian cancer 0.211 0.003 0.019
Negative 3 7 4 3 5 15
Positive 0 9 0 9 5 14
Treatment of CNS metastases 0.537# 0.521# 0.580#
WBRT / / / / 7 7
Steroids / / / / 2 2
Neurosurgery 0 (0) 2 (100.0) 0 (0) 2 (100.0) / 2
Neurosurgery +WBRT 1 (16.7) 5 (83.3) 1 (16.7) 4 (66.7) / 6
Neurosurgery +WBRT + chemotherapy 0 (0) 4 (100.0) 1 (25.0) 3 (75.0) / 4
Neurosurgery + SRS 1 (25.0) 3 (75.0) 1 (25.0) 2 (50.0) / 4
Neurosurgery + SRS + chemotherapy 1 (33.3) 2 (66.7) 1 (33.3) 1 (33.3) / 3
SRS + chemotherapy / / / / 1 1
Abbreviations: NA Not available, KPS Karnofsky performance status, WBRT Whole-brain radiation therapy, SRS Stereotactic radiosurgery.
*Percentage (%) represented the proportion of each group in 19 patients whose tumor tissues were available.
†P values were calculated by comparing CD133-negative vs. CD133-positive groups in 19 patients whose tumor tissues were available.
‡P values were calculated by comparing CD133-negative vs. CD133-positive single cell vs. CD133-positive cluster groups in 19 patients whose tumor tissues
were available.
§P values were calculated by comparing CD133-positive single cell vs. CD133-positive cluster groups in 16 patients whose tumor tissues were stained
CD133 positive.
#P values were calculated by comparing neurosurgery +WBRT +/− chemotherapy vs. neurosurgery + SRS +/− chemotherapy groups.
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mon neurological symptoms and occurred in 17 patients
(58.6%), 12 patients (41.3%), and 5 patients (17.2%), re-
spectively. Less common symptoms included altered men-
tal status, dizziness and speech difficulties. In this cohort,
1 patient (3.4%) had leptomeningeal dissemination, 5 pa-
tients (17.2%) had intraperitoneal relapse before thedisease metastasized to CNS, and 13 patients (44.8%)
developed concurrent metastases to other organs at the
time of the diagnosis of intracranial lesions.
Among the 29 patients, a multimodal approach (com-
bination of at least two treatment modalities including
neurosurgery, whole-brain radiation therapy [WBRT], ste-
reotactic radiosurgery [SRS] and chemotherapy) was the
Table 4 CD133 expression in primary EOC and
corresponding CNS metastatic sites
CD133 expression status No. of CD133- (P) No. of CD133+ (P)
No. of CD133- (M) 3 0
No. of CD133+ (M) 7* 9
Abbreviations: P Primary tumors, M Corresponding CNS metastatic sites.
P value = 0.211.
*Discordant cases.
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The remaining patients received a monotherapy of either
WBRT, neurosurgery, or steroids (7, 2, and 2 patients re-
spectively). Of the 19 neurosurgeries performed either
alone or in combination with other modalities, 9 (47.4%)
cases were solitary CNS metastases and 10 (52.6%) cases
represented multiple lesions.
Immunohistochemical study of CD133 in primary EOC
and CNS metastases
Expression of CD133 in primary and metastatic tumor
tissues was present in the membrane and/or cytoplasm,
sometimes with a low level of heterogeneity (Figure 1A-D).
CD133+ staining was observed in 14 out of 29 (48.3%) pri-
mary EOC samples with CNS metastases, 6 out of 31
(19.4%) EOC samples without CNS metastases and 16 out
of 19 (84.2%) CNS metastatic tissue samples. The number
of CD133+ tumor cells ranged from 0% to 39% (mean 6%)
in primary EOC with CNS metastases, from 0% to 33%
(mean 2%) in EOC without CNS metastases, and from
0% to 42% (mean 10%) in the 19 CNS metastatic tissue
samples. The distribution of CD133 expression in primary
EOC with CNS metastases is summarized in Table 1 ac-
cording to the clinicopathologic characteristics. Absence
of CD133 expression in primary EOC with CNS metas-
tases was associated with a higher platinum sensitivity.
Specifically, CD133+ expression was observed in 25.0%
(4 of 16) patients with platinum-sensitive disease vs. 83.3%
(10 of 12) in platinum-resistant disease (P = 0.006). Simi-
lar finding was observed in recurrent EOC without CNS
metastases, with CD133+ expression being detected in
5.2% (1 of 19) platinum-sensitive patients vs. 40.0% (4 of
10) platinum-resistant patients (P = 0.036). No other asso-
ciation was found between CD133+ expression and the
clinicopathologic parameters in either EOC with CNS me-
tastases or control group (data not shown).
Results of CD133 expression analysis in CNS metastatic
tissue are shown in Table 3. The expression level was high
in CNS metastases, suggesting that the categorization of
patients in CD133+ vs. CD133- may have been biased con-
sidering the possible quantitative effect of CD133+ cells
[20]. To reduce the bias, we divided samples into a single
cell (Figure 1C) and cluster-type staining based on their
topology. A cluster was defined as an aggregation of more
than five CD133+ cells [21] and sections with at least one
cluster were classified as “cluster + type”. CD133+ cell
clusters (Figure 1D) more frequently occurred in CNS
metastases (63.2%, 12 of 19 patients) but were relatively
uncommon in primary EOC (24.1%, 7 of 29 patients). This
difference was significant (P = 0.015). However, CD133+
cell cluster formation in CNS metastases was associated
with CD133+ expression in primary EOC (P = 0.003)
(Table 3). There was no correlation between the per-
centage of CD133+ cells in the metastases and thecorresponding primary EOC; but there was a correlation
between the CD133+ category (samples with >0% CD133+
cells) in the metastases and primary EOC (Spearman’s
rank correlation coefficient, r = 0.706; P = 0.001). CD133
expression status was concordant between primary and
CNS metastatic sites in 12 patients (63.2%) and no statis-
tically significant difference was observed (kappa = 0.289,
P = 0.211, Table 4). Of the 7 discordant cases, all had
CD133+ expression in CNS metastases but not in primary
tumors. We analyzed the difference between the concor-
dant and discordant cases according to clinicopathologic
parameters at the time of initial EOC diagnosis and found
no differences (data not shown). There was no other asso-
ciation observed between CD133+ expression (or cluster
formation) and the clinicopathologic parameters examined
(Table 3).
Risk factors associated with the development of CNS
metastases
As shown in Table 2, CD133+ expression was the only
factor associated with an increased risk of CNS metasta-
ses in recurrent EOC patients, which was significantly
different between EOC patients with and without CNS
metastases (P = 0.018).
Results of binary logistic regression showed that lymph
node metastasis at initial surgery and CD133 expression
were significantly associated with an increased risk of
CNS metastases (data not shown).
Multivariate logistic regression demonstrated CD133 ex-
pression in primary tumor as the only independent risk
factor for CNS metastases (HR, 4.72; 95% CI, 1.10-20.41;
P = 0.037) (Table 5).
Risk factors associated with shorter times to the diagnosis
of CNS metastases
Among the 29 patients with CNS metastasis, the median
time to the diagnosis of CNS metastases was 23.5 months
(range from 6.2-75.0 months).
A univariate analysis of risk factors associated with a
shorter time to CNS metastases is shown in Table 6. Fac-
tors including International Federation of Gynecology and
Obstetrics (FIGO) stage, extent of surgical resection, lymph
node metastasis at initial surgery, platinum sensitivity, and
CD133 expression were significantly related to the time of
the CNS metastases diagnosis.
Table 5 Multivariate logistic regression for risk of CNS
metastases
Variable HR (95% CI) P value
Age > = 60 yrs 2.74 (0.60-12.58) 0.195
FIGO stage: 3,4 vs. 1,2 2.79 (0.42-18.52) 0.289
Pathology: serous vs. non-serous 1.87 (0.42-8.23) 0.409
Surgical resection: TAH + BSO vs.
Limited and Biopsy
1.39 (0.26-7.59) 0.703
Presence of lymph node metastasis 4.17 (0.94-16.67) 0.053
Presence of ascites 1.84 (0.23-14.71) 0.566
Platinum resistance 4.15 (0.83-20.83) 0.083
CD133 expression 4.72 (1.10-20.41) 0.037
Abbreviations: TAH Total abdominal hysterectomy, BSO Bilateral salpingo-
oophorectomy.









<60 16 (55.2) 27.3 (17.5-37.1)
> = 60 13 (44.8) 22.9 (14.4-29.4)
FIGO stage 0.021
1,2 3 (10.3) 45.1 (10.5-79.7)
3,4 26 (89.7) 22.7 (18.7-26.7)
Pathology of primary cancer 0.595
Serous 16 (55.2) 25.7 (16.5-34.9)
Non-serous 13 (44.8) 22.7 (20.8-24.6)
Histological grade 0.354
1,2 5 (21.7) 27.7 (18.7-36.7)
3, 18 (78.3) 21.9 (17.1-26.7)
Extent of surgical resection <0.0001*
TAH + BSO 23 (79.3) 27.7 (23.0-32.4)
Limited 5 (17.2) 16.3 (15.4-17.2)
Biopsy 1 (3.4) 6.2
Lymph node metastasis 0.026
No 11 (37.9) 31.7 (24.4-39.0)
Yes 18 (62.1) 22.0 (21.6-22.4)
Ascites at the time of primary surgery 0.153
No 10 (34.5) 29.0 (22.8-35.2)
Yes 19 (65.5) 22.1 (21.2-23.0)
Adjuvant therapy 0.683†
Chemotherapy 25 (86.2) 25.3 (20.4-30.2)
Chemotherapy +
Radiotherapy
3 (10.3) 21.9 (14.9-28.9)
None 1 (3.4) 23.5
Platinum sensitivity <0.0001
Sensitive 16 (57.1) 29.0 (16.8-41.2)
Resistant 12 (42.9) 16.3 (13.6-19.0)
CD133 expression 0.033
Negative 15 (51.7) 29.0 (20.9-37.1)
Positive 14 (48.3) 19.8 (11.7-27.9)
Abbreviations: TAH Total abdominal hysterectomy, BSO Bilateral salpingo-
oophorectomy.
*P <0.0001 for TAH + BSO vs. Limited and for TAH + BSO vs. Biopsy, P = 0.025
for Limited vs. Biopsy.
†P = 0.683 for Chemotherapy vs. None, P = 0.956 for Chemotherapy vs.
Chemotherapy + Radiotherapy, P = 0.918 for Chemotherapy + Radiotherapy
vs. None.
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gical resection (HR, 5.91; 95% CI, 1.02-34.24; P = 0.047)
and platinum resistance (HR, 5.41; 95% CI, 1.63-17.99;
P = 0.006) were independent predictors for a shorter time
to the diagnosis of CNS metastases (Table 7, Figure 2).
Prognostic factors associated with OS after the diagnosis
of CNS metastases
The median OS since the primary EOC was 3.35 years
(95% CI, 2.75-3.95 years), with 1-, 3-, and 5-year survival
probabilities being 96.6%, 62.1%, and 17.2%, respectively.
The median OS since CNS metastases was 13.2 months
(95% CI, 6.9-19.5 months), with 6-month, 1-year, and
3-year survival probabilities being 82.8%, 55.2%, and 9.2%,
respectively. Twenty-seven of 29 (93.1%) patients died
within the follow-up period. Of the 19 patients whose
treatment included neurosurgery, the median OS since
the diagnosis of CNS metastases was 17.0 months (95%
CI, 11.6-22.4 months), which was significantly longer than
that of the 10 patients treated without neurosurgery
(8.0 months, 95% CI, 4.5-16.2 months, P = 0.004).
Univariate analysis showed significant association bet-
ween OS and the following parameters: platinum sensitiv-
ity, CD133 expression in primary EOC, number of CNS
metastases, treatment strategies for CNS metastases, and
CD133 expression in CNS metastases (Table 8). Shorter
time to CNS metastases diagnosis was not associated with
decreased survival.
Multivariate Cox proportional hazards model including
variables with P <0.05 in the univariate analysis were ana-
lyzed to evaluate independent predictors of OS. Platinum
resistance (HR, 5.13; 95% CI, 1.28-20.57; P = 0.021), multi-
modal therapy incorporating SRS for CNS metastases
(HR, 0.12; 95% CI, 0.03-0.55; P = 0.007), and CD133 clus-
ter formation in CNS metastases (HR, 12.08; 95% CI,
1.55-94.16; P = 0.017) were found to influence OS signifi-
cantly and independently (Table 9, Figure 3).Discussion
CNS metastases represent a late manifestation of EOC
and are associated with extremely poor prognosis re-
gardless of the treatment [1,4]. One of the main findings
of this study is that the extent of surgical resection and
Table 7 Multivariate Cox proportional hazards regression
for time to CNS metastases
Variable HR (95% CI) P value
Age > = 60 yrs 1.38 (0.50-3.82) 0.536
FIGO stage: 3,4 vs. 1,2 3.65 (0.38-35.21) 0.263
Surgical resection: TAH + BSO vs.
Limited and Biopsy
5.91 (1.02-34.24) 0.047
Presence of lymph node metastasis 2.65 (0.91-7.71) 0.074
Platinum resistance 5.41 (1.63-17.99) 0.006
CD133 expression 1.24 (0.46-3.34) 0.665
Abbreviations: TAH Total abdominal hysterectomy, BSO Bilateral salpingo-
oophorectomy.
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risk predictors for time to CNS metastases. This is in
keeping with previous observations that the size of re-
sidual tumor after surgery is one of the most important
prognostic factors for survival of advanced EOC [22,23].
Our results reemphasize that all attempts should be made
to achieve complete cytoreduction or optimal (<1 cm) re-
sidual disease in order to prolong the survival of EOC pa-
tients and delay disease progression and metastasis.
Given that the current guidelines for the management
of EOC should be individualized according to the patient
status, gynecologists must balance the risk of rapid me-
tastases against the costs and adverse effects that ac-
company aggressive interventions. It has been shown by
Sehouli et al. [7] and confirmed by our study that pla-
tinum sensitivity is an independent prognostic factor for
a favorable outcome in patients with CNS metastases
from EOC. In addition, our results showed a detrimental
impact of platinum resistance on the time to the de-
velopment of CNS metastases. Taken together, these fin-
dings suggest that patients who are unable to achieve
optimal cytoreduction and/or who present with platinum
resistance might benefit from more aggressive treatment
intended to better control the primary disease, and have aFigure 2 Kaplan–Meier curves of cumulative central nervous system (
patients with CNS metastases from ovarian cancer. (A) Total abdomina
limited surgery or biopsy. Result of multivariate Cox regression; HR, 5.91; 95
disease. Result of multivariate Cox regression; HR, 5.41; 95% CI, 1.63-17.99; Ppossible delay of CNS metastases. Physicians should also
pay more attention to the presence of neurological symp-
toms in this group of patients and arrange CNS imaging
for early diagnosis and prompt treatment of metastases. In
addition, having a biomarker, which is associated with the
metastatic disease would allow this population of patients
to be screened appropriately. Our results indicate a posi-
tive association between CD133+ expression in primary
tumor and increased risk of CNS metastases, and thus
hold promise for further validation of the application of
this molecule as a biomarker in disease monitoring and
management.
Regarding the prognostic factors for CNS metastases
from EOC, the findings that platinum sensitivity [7] and
multimodal treatment [9,12] have a positive impact on
OS are supported by our results. Moreover, we for the
first time compared the expression of CD133, a putative
CSC marker, in both the primary EOC and its corre-
sponding CNS metastases, and described its predictive
role for CNS metastases.
The fraction of CD133+ cells are enriched in several
kinds of solid tumors including the ovarian cancer, which
are presented with enhanced resistance to platinum-based
chemotherapy [14,24]. To this end, patients with CD133+
tumor cells are more likely to experience platinum resis-
tance (also confirmed by our results) and thus a less than
satisfactory outcome of the primary cancer management.
In addition, CD133+ ovarian cancer cells display a poten-
tial of CSCs [14], which may be associated with more ag-
gressive tumor growth and poor prognosis in ovarian
cancer patients [17]. Several recent studies have also dem-
onstrated CD133 as a metastasis-related molecule. Specifi-
cally CD133 + CXCR4+ cancer cells had a high metastatic
capacity in liver metastases of colorectal tumors [25],
metastatic pancreatic cancers [26], while overexpression
of CD133, CD44v6 and human tissue factor was asso-
ciated with pancreatic carcinoma metastasis [27]. In agree-
ment with these, we found that CD133+ expression inCNS)-metastases-free survival (time to CNS metastases) in 29
l hysterectomy + bilateral salpingo-oophorectomy (TAH + BSO) vs.
% CI, 1.02-34.24; P = 0.047. (B) Platinum-resistant vs. platinum-sensitive
= 0.006.










<60 16 (55.2) 15.3 (3.7-26.9)
> = 60 13 (44.8) 9.4 (4.9-13.9)
FIGO stage 0.069
1,2 3 (10.3) 32.3 (16.9-47.7)
3,4 26 (89.7) 11.7 (9.5-13.9)
Pathology of primary cancer 0.824
Serous 16 (55.2) 11.7 (9.9-13.5)
Non-serous 13 (44.8) 15.3 (6.1-24.5)
Histological grade 0.391
1,2 5 (21.7) 22.7 (3.7-41.7)
3, 18 (78.3) 11.7 (9.6-13.8)
Extent of surgical resection 0.211*
TAH + BSO 23 (79.3) 13.2 (7.6-18.8)
Limited 5 (17.2) 16.2 (4.5-19.3)
Biopsy 1 (3.4) 1.0
Lymph node metastasis 0.372
No 11 (37.9) 20.4 (8.4-32.4)
Yes 18 (62.1) 11.7 (9.4-14.0)
Ascites at the time of
primary surgery
0.421
No 10 (34.5) 15.3 (1.7-28.9)
Yes 19 (65.5) 12.5 (9.9-15.1)
Adjuvant therapy 0.071†
Chemotherapy 25 (86.2) 15.3 (8.0-22.6)
Chemotherapy + Radiotherapy 3 (10.3) 7.0 (1.5-12.4)
None 1 (3.4) 32.3
Platinum sensitivity 0.033
Sensitive 16 (57.1) 15.3 (0.5-30.1)
Resistant 12 (42.9) 9.4 (0.1-18.9)
CD133 expression in primary cancer 0.001
Negative 15 (51.7) 25.5 (10.4-40.6)
VPositive 14 (48.3) 9.4 (2.4-16.4)
KPS score 0.412
> = 80 14 (48.3) 13.2 (1.0-29.2)
<80 15 (51.7) 12.5 (1.1-23.9)
No. of metastases 0.027
Single 11 (37.9) 25.5 (12.6-38.4)
Multiple 18 (62.1) 9.4 (4.4-14.4)
Table 8 Univariate analysis for predictors of OS since CNS
metastases (Continued)
Prior cancer relapse before the diagnosis of CNS metastasis 0.053
No 24 (82.8) 15.3 (6.4-24.2)
Yes 5 (17.2) 9.4 (3.3-21.2)
Presence of extracranial disease 0.458
No 16 (55.2) 13.2 (3.1-23.3)
Yes 13 (44.8) 12.5 (5.4-19.6)
Treatment of CNS metastases 0.027‡
Steroids 2 (6.9) 1.0 (0–5.292)
Unimodal (WBRT or
Neurosurgery)




10 (34.5) 13.2 (7.5-18.9)
Multimodal including SRS
(SRS +/− neurosurgery +/−
chemotherapy)
8 (27.6) 27.3 (15.1-39.5)
CD133 expression in CNS metastases 0.005§
Negative 3 (15.8) 42.1 (31.4-46.2)
Positive single cell 4 (21.1) 27.3 (25.1-29.6)
Positive cluster 12 (63.2) 11.6 (8.5-14.7)
Time to CNS metastases (mo) 0.122
<23.5 14 (48.3) 7.6 (0.78-20.25)
> = 23.5 15 (51.7) 15.3 (1.41-29.19)
Abbreviations: TAH Total abdominal hysterectomy, BSO Bilateral salpingo-
oophorectomy, KPS Karnofsky performance status, WBRT Whole-brain radiation
therapy, SRS Stereotactic radiosurgery.
*P = 0.211 for TAH + BSO vs. Limited, P <0.0001 for TAH + BSO vs. Biopsy,
P = 0.025 for Limited vs. Biopsy.
†P = 0.071 for Chemotherapy vs. Chemotherapy + Radiotherapy, P = 0.412 for
Chemotherapy vs. None, P = 0.182 for Chemotherapy + Radiotherapy vs. None.
‡P = 0.027 for Steroids vs. Unimodal, P <0.0001 for Steroids vs. Multimodal
including WBRT, P = 0.001 for Steroids vs. Multimodal including SRS, P = 0.022
for Unimodal vs. Multimodal including WBRT, P <0.0001 for Unimodal vs.
Multimodal including SRS, P = 0.020 for Multimodal including WBRT vs.
Multimodal including SRS.
§P = 0.005 for negative vs. positive cluster , P = 0.023 for positive single cell vs.
positive cluster, P = 0.075 for negative vs. positive single cell.
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http://www.biomedcentral.com/1471-2407/14/829primary EOC was the only independent risk factor for
CNS metastases. The fact that all other clinicopathologic
parameters were not risk factors indicated that without as-
sessment of the molecular behavior of the primary disease,
it may be hard to identify recurrent EOC patients with
high risk of CNS metastases who need close observation.
Our data do not support the role of CD133 expression
in primary EOC as a significant predictor of the time to
CNS metastases diagnosis or subsequent survival of pa-
tients with CNS metastases. This is despite CD133 asso-
ciation with platinum sensitivity, a predictor for both
CNS-metastases-free survival and OS and could be attrib-
uted to a possible bias due to a small number of patients.
Furthermore, CD133 may influence patient survival in-
dependently of its association with platinum sensitivity, as
was shown in a colon cancer study, which found a
Table 9 Multivariate Cox proportional hazards regression
for OS after CNS metastases
Variable HR (95% CI) P value
Platinum resistance 5.13 (1.28-20.57) 0.021
CD133 expression in primary ovarian cancer 2.82 (0.66-12.17) 0.163
Multiple CNS metastases 1.11 (0.20-6.12) 0.921
Multimodal therapy including SRS
(SRS +/− neurosurgery +/− chemotherapy)
for CNS metastases
0.12 (0.03-0.55) 0.007
CD133 cluster formation in CNS metastases 12.08 (1.55-94.16) 0.017
Abbreviations: TAH Total abdominal hysterectomy, BSO Bilateral salpingo-
oophorectomy, KPS Karnofsky performance status, WBRT Whole-brain radiation
therapy, SRS Stereotactic radiosurgery.
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http://www.biomedcentral.com/1471-2407/14/829downregulated CD133 expression in tumor epithelial cells
after metastatic transition [28]. A transformation of pri-
mary cancer with CD133+ cells into metastasis consists of
CD133- cells was observed, indicating that CD133- cells
are also potent in tumor initiation [28]. On the other
hand, when comparing EOC patients with and without
CNS metastases, the overall survival was significantly bet-
ter in CD133- expressing cases. Thus CD133 may be con-
sidered a hallmark of malignancy of primary disease with
respect to CNS metastasis. However, its biological func-
tion might not be the only rate-limiting step considering
that multiple molecular events are known to regulate the
process of tumor metastasis [29].
We were able to show that CD133 cluster formation in
CNS metastases could serve as a prognostic factor for OS
and that CD133 clusters were significantly associated with
prior CD133+ expression in primary EOC. However, the
CD133+ expression was greater in the metastatic tissue. It
is not inconceivable that the microenvironment for CSCs
represented by CD133+ staining may be completely dif-
ferent in the CNS compared to the ovary affecting the
proliferative or self-renewal potential of CSCs. Also, it has
been demonstrated that a significant number of genes areFigure 3 Kaplan–Meier curves of cumulative overall survival after the
patients with CNS metastases from ovarian cancer. (A) Platinum-resista
HR, 5.13; 95% CI, 1.28-20.57; P = 0.021. (B) Multimodal therapy including stere
radiation therapy (WBRT) vs. unimodal therapy with WBRT or neurosurgery vs.
including SRS vs. others: HR, 0.12; 95% CI, 0.03-0.55; P = 0.007. (C) CD133 clust
regression; HR, 12.08; 95% CI, 1.55-94.16; P = 0.017.differentially expressed in metastatic disease compared to
primary ovarian cancer [30]. To better understand the role
of a “stemness” marker of CD133 in the progression and
metastasis of primary tumor, further studies are warranted
preferably by analyzing a panel of potential “stemness”
markers such as CD44, ALDH, EpCAM as well as CD133
in the future [14,31].
In most cases with CNS metastases from EOC, multi-
modal treatment approaches have been proven to greatly
increase the therapeutic potential and significantly prolong
the OS compared to unimodal approaches [3,6,8,9,12,32].
Though the optimal combination of modalities remains a
matter of investigation, studies with a large sample size
as well as meta-analyses showed that a combination of
WBRT and neurosurgery with or without chemotherapy
was most commonly applied with promising results. SRS
has come into focus for the treatment of CNS metastases
in recent years, as it is a noninvasive modality that pro-
vides good local control [33,34]. In addition, SRS is cap-
able of treating lesions inaccessible to neurosurgery with
an equivalent efficiency, which accounts for 50% of single
CNS metastases [1]. Previous study on monotherapy with
SRS has shown a remarkable increase in survival com-
pared to WBRT (29 vs. 6 months) [35]. In the current
study, improved survival was observed in patients treated
with multimodal approach including SRS, compared to
steroids, WBRT or neurosurgery alone, and multimodal
approach including WBRT (27.3 vs. 1.0 vs. 8.0 vs.
13.2 months, P <0.05 in all instances, Figure 3B). In agree-
ment with Kim et al. [11], we also found that the treatment
modality including SRS was also the most important inde-
pendent prognostic factor for CNS metastases from EOC.
This study has several limitations. Although we found
that CD133 expression was a risk factor for the deve-
lopment of CNS metastases and that non-optimal cyto-
reduction and platinum resistance were risk factors
for shorter time to the diagnosis of CNS metastases,diagnosis of central nervous system (CNS) metastases in 29
nt vs. platinum-sensitive disease. Result of multivariate Cox regression;
otactic radiosurgery (SRS) vs. multimodal therapy including whole-brain
steroids. Result of multivariate Cox regression; multimodal therapy
er formation vs. CD133 negative or single cell. Result of multivariate Cox
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http://www.biomedcentral.com/1471-2407/14/829identification of other potential markers such as tran-
scriptional factors [36-39] and immune factors [40-42]
in primary EOC to indicate future cisplatin-refractory
CNS-metastasis in EOC patients was outside the scope
of this study. A genome-wide transcription analysis may
identify other candidate molecules that have different
expression levels in EOC patients with and without CNS
metastases. Since this was a retrospective study, com-
plete data were not available for all patients. Further-
more, our data represents the experience of a single
institution and may not be fully generalizable. Since the
number of patients with CNS metastases is small in any
single institution, multicenter studies are needed to in-
crease the statistical power. Finally, because CNS metas-
tases in EOC patients often represent as a palliative
situation, the quality-of-life should also be considered as
an important endpoint.
Conclusions
In conclusion, our results show a significant association
between positive expression of CD133 in primary EOC
and an increased risk of CNS metastases. Higher plat-
inum sensitivity is associated with a longer time to de-
velop CNS metastases and a better prognosis of CNS
metastases. Absence of CD133 clusters in metastatic tis-
sue and use of multimodal treatment including SRS are
associated with prolonged survival. Further investigation
is warranted to elucidate the true nature of the associ-
ation between platinum sensitivity, CD133 expression,
and disease outcomes.
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